Novavax, Inc.

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
8.250 ^USD	+4.83%		-6.73%	+22.77%

Jan. 22	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE
Jan. 20	Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant	DJ

Novavax Stock Edges Higher After 2025 Adjusted Revenue Forecast Raised

Published on 11/06/2025 at 09:58 am EST

MT Newswires

Latest news about Novavax, Inc.

Jan. 22	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE
Jan. 20	Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant	DJ
Jan. 20	Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc	CI
Jan. 20	Novavax Enters Non-Exclusive Licensing Deal With Pfizer	MT
Jan. 20	Novavax Inc enters license agreement with Pfizer - SEC filing	RE
Jan. 20	Novavax signs licensing agreement with Pfizer for vaccine development	RE
Jan. 20	Novavax enters license agreement with Pfizer for vaccine development	RE
Jan. 14	Novavax, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 04:30 PM
Jan. 07	Imunon, Inc. Announces Chief Financial Officer Changes, Effective January 14, 2026	CI
Dec. 12	Rate Cuts Can't Buy Confidence
Dec. 09	Fda probes if Covid shots might be linked to deaths of adults - Bloomberg News	RE
Dec. 01	Moderna, Other Pharma Stocks Close Lower After US FDA Reportedly Plans to Toughen Vaccine Approval	MT
Nov. 19	Novavax, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 04:30 PM
Nov. 12	Shah Capital pushes for Novavax sale	RE
Nov. 12	Shah Capital pushes for Novavax sale, warns of proxy fight	RE
Nov. 12	Shah Capital Urges Novavax Board to Address Operational Inefficiencies and Consider Strategic Merger to Maximize Vaccine Potential	CI
Nov. 11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
Nov. 10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
Nov. 06	Novavax, Inc., Q3 2025 Earnings Call, Nov 06, 2025
Nov. 06	Novavax delays profitability target with eyes on Sanofi-led launches	RE
Nov. 06	Novavax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 06	Novavax Stock Edges Higher After 2025 Adjusted Revenue Forecast Raised	MT
Nov. 06	Earnings Flash (NVAX) Novavax, Inc. Reports Q3 Revenue $70.4M, vs. FactSet Est of $42.1M	MT
Nov. 06	Earnings Flash (NVAX) Novavax Posts Q3 Net Loss $1.25 a Share, vs. FactSet Est of $1.20 Loss	MT
Nov. 06	Novavax beats quarterly revenue estimates on milestone payment	RE

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâ€™s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Employees

952

Sector

Biotechnology & Medical Research

Calendar

Mar. 03 - Q4 2025 Earnings Release (Projected)

More about the company